Sam Altman
No public longevity impact is supported here. The only cited paper is by Soya S Sam on an HIV assay, not Sam Altman, so crediting Altman would be spreadsheet cosplay.
9 / 100investorself-experimenterScoring AI engine · v0.4.0
Role
investorhigh confidence
This is the actual channel: he put very large equity capital into Retro Biosciences and seeded the company. Delete the money and most of his longevity impact here disappears.
Inside the AI used by Sam Altman's $1B+ longevity startup ↗Inside the AI used by Sam Altm…–Free Radicals – Apple Podcas ↗
also: self-experimenter
Dimension breakdown
This score rates longevity commitment only. The role tags above — scientist, investor, and the rest — say what this person is; we don't score those separately.
Evidence is still sparse for this hero. Scores are shown with low-confidence warnings until more source material is harvested.
Future vision
0.0/ 10
The dimension applies, but the provided evidence contains no articulated vision from Sam Altman about ending aging, reversing biological decline, or materially extending healthy lifespan. The only relevant signal is a broad investor bio mentioning a longevity biotech investment footprint, which does not establish a concrete or durable public future vision.
high confidence
Scientific impact
1.0/ 10
There is no credible evidence of Sam Altman's direct scientific output or field-shaping scientific influence in the provided evidence. The only academic citation appears to be for a different person named Soya S Sam, not Sam Altman. The investor bio suggests exposure to longevity biotech and related sectors, but provides no specific scientific achievements, citations, authored work, trials, or independently corroborated translational impact.
low confidence
Capital deployed
1.0/ 10
The dimension applies because Sam Altman is described as an investor with substantial capacity, but the provided evidence contains no specific longevity investments, donations, amounts, institutions, recurring commitments, or catalytic funding. A weak dossier statement says his investment footprint spans longevity biotech, but it gives no names or amounts and has unknown independence, so it cannot support more than a very low score.
low confidence
Strategic taste
1.0/ 10
The dimension applies because Sam Altman is described as an entrepreneur and investor, but the supplied evidence contains almost no concrete longevity-related strategic bets, thesis, timing, stage preference, or counterfactual contribution. A generic statement that his public investment footprint spans longevity biotech is too thin to establish thesis-coherent, early, contrarian, or field-improving strategic taste.
low confidence
Field creation
1.0/ 10
The dimension is applicable, but the provided evidence contains no credible longevity-specific field_creation achievements by Sam Altman. The structured facts report no founded organizations, active organizations, or donation-created programs, and the only relevant biographical note is too general to show he created longevity institutions, programs, categories, communities, protocols, or funding paths.
low confidence
Bravery and conviction
0.0/ 10
The provided evidence does not show any public longevity-related risk-taking, contrarian advocacy, career sacrifice, sustained conviction under criticism, unusually large bet relative to capacity, or self-experimentation by Sam Altman. A broad investment footprint that includes longevity biotech is not enough to establish bravery or conviction under this rubric.
medium confidence
Multiplier effect
2.0/ 10
The dimension is applicable, but the supplied evidence contains almost no concrete longevity-specific multiplier effects. One dossier-style source says Altman has a broad investment footprint that includes longevity biotech, but it does not identify specific longevity investments, organizations, collaborators, follow-on projects, or independently corroborated field-level leverage.
low confidence
Vision
Destination
He reportedly helped Betts- LaCroix shape the company’s ten- year longevity goal during an off- site retreat at Altman’s ranch in Napa Valley, according to Endpoint News.
He reportedly helped Betts- LaCroix shape the company’s ten- year longevity goal during an off- site retreat at Altman’s ranch in Napa Valley, according to Endpoint News.
Altman’s involvement with Retro runs deep. He reportedly helped Betts- LaCroix shape the company’s ten- year longevity goal during an off- site retreat at Altman’s ranch in Napa Valley, according to Endpoint News.
Sam Altman’s Retro Biosciences Aims to Add a Decade to Human Life
I hope to use a Retro therapy someday!
He says he’s emptied his bank account to fund two other very different but equally ambitious goals: limitless energy and extended life span.
He says he’s emptied his bank account to fund two other very different but equally ambitious goals: limitless energy and extended life span.
He says he’s emptied his bank account to fund two other very different but equally ambitious goals: limitless energy and extended life span.
Path
No canonical quotes yet.
Strategy
No strategy evidence was available for Sam Altman in the provided materials. Investment, donation, and organization-founding records are unsupported here. Stage preference, area focus, geography focus, risk appetite, and time horizon are therefore unknown. No collaborators or notable longevity-related bets can be identified from the supplied evidence.
UnknownUnknown
Portfolio
Investments
Donations
No public rows yet.
Organizations founded
No public rows yet.
Scientific output
h-index-
Citations-
Papers1
Trials0
Bravery and conviction
Belief evolution
Self-experimentation
Connections
Companies
Collaborators and lineage
No public rows yet.
Criticisms